Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2018

Revenue Recognition

Schedule of disaggregation of revenue by test families

	Three months ended
	March 31,
	2018		2017
(Amounts in thousands)			(As Revised)
Sales of genetic tests
Panorama NIPT	$	33,267	$	32,559
HCS		18,262		12,953
Other genetic tests		2,740		2,882
Product revenues		54,269		48,394
Licensing and other
Constellation		1,305		988
Other		6,766		—
Licensing and other revenues		8,071		988
Total revenues	$	62,340	$	49,382

Schedule of disaggregation of revenue by sales vertical

	Three months ended
	March 31,
	2018		2017
(Amounts in thousands)			(As Revised)
Insurance carriers	$	44,142	$	38,840
Laboratory partners		14,888		8,093
Patients		3,310		2,449
Total revenues	$	62,340	$	49,382

Schedule of total revenue by geographic area

	Three months ended
	March 31,
	2018		2017
(Amounts in thousands)			(As Revised)
United States	$	50,364	$	43,825
Americas, excluding U.S.		850		700
Europe, Middle East, India, Africa		9,322		3,216
Other		1,804		1,641
Total revenues	$	62,340	$	49,382

Schedule of changes in the balances of the Company?s contract assets and liabilities

	Balance at						Balance at
	December 31,						March 31,
	2017		Additions		Deductions		2018
(Amounts in thousands)	(As Revised)
Assets:
Accounts receivable	$	44,089	$	55,004	$	(48,767)	$	50,326
Liabilities:
Deferred revenue, current portion	$	1,420	$	964	$	(941)	$	1,443
Deferred revenue, long-term	$	—	$	35,462	$	—	$	35,462